Safety of an Oral HIV Vaccine in HIV Uninfected Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT00062530

Recruitment Status : Unknown

Verified September 2008 by National Institute of Allergy and Infectious Diseases (NIAID).
Recruitment status was: Not yet recruiting

First Posted : June 12, 2003

Last Update Posted : September 26, 2008

Sponsor:

Information provided by:

National Institute of Allergy and Infectious Diseases (NIAID)

Study Description

Brief Summary:

This study will test the safety of and immune response to an oral HIV vaccine in healthy volunteers. The vaccine in this study uses a weakened bacterium called Salmonella typhi to deliver an HIV gene into the body through the mouth. The body then produces an HIV protein from the gene; this protein stimulates an anti-HIV immune response. The vaccine contains only one of the many substances that HIV needs to make more copies of itself, so the vaccine itself cannot cause HIV or AIDS.

Condition or disease	Intervention/treatment	Phase
HIV Infections	Biological: SCBaL/M9	Phase 1

Detailed Description:

The transmission of HIV-1 by both sexual and parenteral routes makes it likely that a successful preventive vaccine against this virus will need to induce protective immunity in both mucosal and systemic compartments. The long-term objective of this program is to develop an HIV-1 vaccine that elicits protective immunity in both the mucosal and systemic compartments.

The study will evaluate the safety and immunogenicity of an oral recombinant Salmonella typhi HIV-1 gp120 vaccine (SCBaL/M9) in healthy human volunteers. This will be the first study in volunteers to use an intracellular bacterium to deliver a recombinant vector vaccine mucosally. The study will also develop an Env immunogen that elicits a broader spectrum of neutralizing antibodies than gp120 and that can be delivered by Salmonella typhi or as a soluble protein immunogen.

This is a Phase I dose-escalation study of two vaccine components that will be combined in a larger prime-boost protocol should the desired safety endpoints be obtained. Both components use a conformationally constrained gp120 that expresses epitopes recognized by broadly neutralizing antibodies. The priming immunogen will be the conformationally constrained gp120 gene delivered orally by live attenuated Salmonella typhi. The boosting immunogen will be a soluble subunit protein comprised solely of the conformationally constrained gp120.

All participants in this study will receive the vaccine. Participants will be randomized to different vaccine doses. Participants will have eight study visits over 20 weeks. Study visits will include brief medical interview, physical exam, blood and urine tests, and counseling on avoiding HIV infection and pregnancy. Participants will be tested for HIV infection 3 times during the study.

Study Design


Study Type :	Interventional (Clinical Trial)
Estimated Enrollment :	38 participants
Allocation:	Randomized
Intervention Model:	Parallel Assignment
Masking:	None (Open Label)
Primary Purpose:	Prevention
Official Title:	Development of an Oral Prime-Boost AIDS Vaccine to Elicit Broadly Neutralizing Antibodies Against HIV-1

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS

U.S. FDA Resources

Arms and Interventions

Arm	Intervention/treatment
Experimental: 1 All participants will receive oral vaccine at study entry, although dosage will vary	Biological: SCBaL/M9 Oral recombinant Salmonella typhi HIV-1 gp120 vaccine

Outcome Measures

Primary Outcome Measures :

Safety, as judged by the lack of an immune response to CD4 epitopes or other significant adverse events as defined by the HVTN toxicity tables [ Time Frame: Throughout study ]

Secondary Outcome Measures :

Neutralizing antibody response against HIV-1 [ Time Frame: Throughout study ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:	18 Years to 55 Years (Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria

HIV uninfected
Low risk sexual behavior
Negative for Hepatitis B surface antigen
Negative for Hepatitis C viral sequences and antibody
Availability for follow-up for planned duration of the study (12 months)
Acceptable methods of contraception

Exclusion Criteria

Receipt of HIV vaccines or placebo in a previous HIV vaccine trial
History of immunodeficiency, chronic illness, autoimmune disease, or use of immunosuppressive medications
History of cancer unless there has been surgical excision followed by a sufficient observation period to give a reasonable assurance of cure
Medical or psychiatric condition or occupational responsibilities which preclude compliance with the protocol
History of suicide attempts, recent suicidal ideation, or psychosis
High risk behavior for HIV infection as determined by screening questionnaire
History of injection drug use within 12 months of study entry
Live attenuated vaccines within 60 days of study entry. Medically indicated killed or subunit vaccines (e.g., influenza, pneumococcal) are not exclusionary, but should be given at least 2 weeks away from HIV immunizations.
Use of experimental agents within 30 days of study entry
Receipt of blood products or immunoglobulin within 6 months of study entry
Active syphilis
Active tuberculosis
History of anaphylaxis or serious adverse reactions to vaccines
History of serious allergic reaction to any substance, requiring hospitalization or emergent medical care (e.g., Stevens-Johnson syndrome, bronchospasm, or hypotension)
Pregnant or breastfeeding

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00062530

Contacts


Contact: George K. Lewis, PhD	410- 706-4688	lewisg@umbi.umd.edu

Locations


United States, Maryland
Institute of Human Virology	Not yet recruiting
Baltimore, Maryland, United States, 21201

Sponsors and Collaborators

National Institute of Allergy and Infectious Diseases (NIAID)

Investigators


Principal Investigator:	George K. Lewis, PhD	Univesity of Maryland

More Information


Responsible Party:	Greg K. Lewis, PhD, University of Maryland
ClinicalTrials.gov Identifier:	NCT00062530 History of Changes
Other Study ID Numbers:	P01AI047490 ( U.S. NIH Grant/Contract ) P01AI047490 ( U.S. NIH Grant/Contract )
First Posted:	June 12, 2003 Key Record Dates
Last Update Posted:	September 26, 2008
Last Verified:	September 2008

Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID):


AIDS HIV seronegativity HIV preventive vaccine

Additional relevant MeSH terms:


HIV Infections Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral	Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Vaccines Immunologic Factors Physiological Effects of Drugs

To Top